10th Complement-Based Drug Development Summit

Memo

Capitalizing on Late-Stage Clinical Success, Strengthening Target and Modality Differentiation and Translating Complement into Ocular, CNS, Oncology and Autoimmune Indications The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies, developers are focused on identifying the right targets, modalities, and indications to drive differentiation and patient impact. Recent milestones, including Regeneron's cemdisiran advancing through FDA and EMA review and Biogen's acquisition of Apellis, highlight the growing momentum and investment shaping the next era of complement therapeutics. As the industry's only dedicated forum uniting complement leaders, this meeting will address the strategic and scientific priorities shaping the next generation of complement therapeutics, including: - Advancing clinical success through biomarker innovation, improved target engagement strategies, robust trial design, and smarter indication selection to de-risk development- Benchmarking next-generation modalities across siRNA, gene therapy, biologics, and novel delivery technologies to improve durability, efficacy, safety, and patient outcomes- Expanding beyond C3 and C5 to evaluate intracellular complement biology, emerging targets, novel mechanisms, and combination approaches shaping the next generation of complement therapeutics- Unlocking growth beyond renal disease by assessing the translational and clinical opportunity across neurodegenerative, ocular, autoimmune, haematological, oncology, and acute indications URLs:Tickets: https://go.evvnt.com/3776267-2?pid=5569Brochure: https://go.evvnt.com/3776267-3?pid=5569 Prices:Drug Developer Pricing - Full Access Pass (Conference + Workshop Day): USD 4397.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 3099.00,Academic Pricing - Full Access Pass (Conference + Workshop Day): USD 3797.00,Academic Pricing - 2 Day Pass (Conference Only): USD 2699.00,Service Provider Pricing - Full Access Pass (Conference + Workshop Day): USD 5297.00,Service Provider Pricing - 2 Day Pass (Conference Only): USD 3299.00 Speakers: Lori Taylor Senior Vice President, Portfolio Strategy and Operations Annexon Biosciences, Stephen Poor Head, Translational Medicine Apellis Pharmaceuticals, Daniel Benjamin President and Chief Executive Officer Cascade Biotechnology, Viral Kansara Chief Development Advisor NeuParadigm Bio, Dennis Keefe Chief Scientific Officer Complement Therapeutics, Erich Rajkovic Chief Business Officer Stealth Stage Company, Frank Baas Senior Vice President, Research Graviton Biosciences, Edwart Patz Chief Executive Officer Grid Therapeutics, Thomas Ciulla Chief Executive Officer Ikarovec, Niels Riedemann Chief Executive Officer Inflarx, Wendy Naimark Chief Technology Officer Ripple Therapeutics, Daniela Cipolletta Senior Director, Immunology Seismic Therapeutics, Alexandra Lucas Founding Scientist Serpass Biologics, Xiaoming Zou Chief Executive Officer Visirna, Karthik Viswanathan Vice President, Research Visterra, Kelly Loyet Director and Distinguished Scientist Genentech, Norbert Leclair Scientist III Genentech, Karoline Meagher Associate Director, Precision Medicine Regeneron, Mahmud Hossain Senior Scientist Sanof, Ron Gorham Principal Scientist Sanof, Peter Zipfel Professor Leibniz Institute for Natural Product Research, Jena, Germany, Lubka Roumenina Senior Scientist and Team Lead Inserm, Brahm Segal Chair, Internal Medicine Moffitt Cancer Center, Yansong Li Principal Investigator The Geneva Foundation Category: Conferences | Health Date and Time: 8th December 2026 at 8:00 am to 10th December 2026 at 5:00 pm Venue details: Hotel Commonwealth, 500 Commonwealth Avenue, Boston, Massachusetts, 02215, United States